
Home » Amgen completes Onyx merger
Amgen completes Onyx merger
October 2, 2013
Amgen has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Onyx Pharmaceuticals for $125 per share in cash. As announced Aug. 25, the purchase price is $9.7 billion net of estimated Onyx cash.
Approximately 57,698,132 shares were validly tendered and not withdrawn in the tender offer, representing approximately 78.5% of Onyx's outstanding shares. Amgen has accepted for payment and will pay for all validly tendered shares.
All remaining eligible Onyx shares will be converted into the right to receive $125 per share in cash, without interest and less any applicable withholding taxes, the same price paid in the tender offer.
Upcoming Events
-
16Oct
-
25Oct
-
26Oct